Janux Therapeutics (JANX) Return on Sales (2021 - 2026)

Janux Therapeutics (JANX) has 6 years of Return on Sales data on file, last reported at 0.07% in Q1 2026.

• Return on Sales for Q1 2026 came in at 0.07%, up 2.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.08% (changed 0.0% YoY), and the FY2025 annual result was 0.11%, down 5.0% from the prior year.
• Return on Sales advanced to 0.07% in Q1 2026 per JANX's latest filing, from 0.11% in the prior quarter.
• Over five years, Return on Sales peaked at 0.01% in Q2 2024 and troughed at 2.41% in Q2 2025.
• A 5-year average of 0.25% and a median of 0.08% in 2025 frame the typical range for Return on Sales.
• On a YoY basis, Return on Sales climbed as much as 61 bps in 2025 and fell as far as 240 bps in 2025.
• A 5-year view of Return on Sales shows it stood at 0.06% in 2022, then climbed by 15 bps to 0.05% in 2023, then sank by 36 bps to 0.07% in 2024, then sank by 74 bps to 0.11% in 2025, then jumped by 43 bps to 0.07% in 2026.
• Business Quant data shows JANX's Return on Sales at 0.07% in Q1 2026, 0.11% in Q4 2025, and 0.02% in Q3 2025.